Case Fatalities in Hospitalised COVID-19 Patients in the UK

August 24, 2020 updated by: University of Edinburgh

Case Fatalities in Hospitalised COVID-19 Patients in the UK: An ISARIC Study

This study will investigate how the case fatality in hospitalised patients with COVID-19 has changed throughout the pandemic. It will also explore possible mechanisms that could be driving these changes. This analysis will enhance our understanding of the virus, which will be important for researchers and clinicians to respond appropriately.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

70000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with proven or high likelihood of COVID-19 admitted to the 260 UK hospitals enrolled in the ISARIC-4C study

Description

Inclusion Criteria:

  • All patients admitted with a proven or high likelihood of COVID-19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hospitalisations
All hospitalised COVID patients
Other: Patient Characteristics
Characteristics of the patients
Other: COVID-19 treatments
Specific treatments used on COVID-19 patients
Other: Differences in triage
Triage criteria for treating COVID-19 patients
Other: Surge capacity
Capacity of hospitals
Critical care
All hospitalised COVID patients in critical care
Other: Patient Characteristics
Characteristics of the patients
Other: COVID-19 treatments
Specific treatments used on COVID-19 patients
Other: Differences in triage
Triage criteria for treating COVID-19 patients
Other: Surge capacity
Capacity of hospitals

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Case fatality
Time Frame: 23 weeks
The proportion of new admissions with COVID-19 who died over time
23 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Edinburgh

Collaborators

International Severe Acute Respiratory and Emerging Infection Consortium
BREATHE Health Data Research Hub

Investigators

  • Principal Investigator: Annemarie B Docherty, Usher Institute, University of Edinburgh
  • Principal Investigator: Ewen M Harrison, Usher Institute, University of Edinburgh
  • Principal Investigator: Rachel H Mulholland, Usher Institute, University of Edinburgh

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 24, 2020

Primary Completion (ACTUAL)

August 2, 2020

Study Completion (ACTUAL)

August 2, 2020

Study Registration Dates

First Submitted

August 24, 2020

First Submitted That Met QC Criteria

August 24, 2020

First Posted (ACTUAL)

August 26, 2020

Study Record Updates

Last Update Posted (ACTUAL)

August 26, 2020

Last Update Submitted That Met QC Criteria

August 24, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ISARIC_COVID_CF

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Access to all data and samples collected by ISARIC4C are controlled by an Independent Data and Materials Access Committee (IDAMAC), composed of representatives of research funders, academia, clinical medicine, public health and industry. Their job is to ensure that all data and samples are used to generate the greatest possible benefit to humanity, in the shortest possible time.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Patient Characteristics

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe